National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Palbociclib (Ibrance®)

Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.

NCPE Assessment Process Complete
Rapid review received 20/09/2016
Rapid review completed 28/09/2016
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 10/10/2016
Pre-submission consultation 11/11/2016
Submission received from applicant 20/12/2016
Preliminary review sent to applicant 24/05/2017
NCPE assessment re-commenced 30/05/2017
Request for further information from applicant (1) 13/06/2017
NCPE assessment re-commenced 15/06/2017
Request for further information from applicant (2) 16/06/2017
NCPE assessment re-commenced 21/06/2017
Applicant Factual Accuracy Check 04/07/2017
NCPE assessment completed 28/07/2017
Full pharmacoeconomic assessment outcome Reimbursement not recommended 

Following NCPE assessment of the applicant’s submission, cost effectiveness of palbociclib (Ibrance®) for this indication has not been demonstrated, and therefore it is not recommended for reimbursement.


The HSE has approved reimbursement following confidential price negotiations; June 2018